Bharat Biotech Supplying Its Covid-19 Vaccine Covaxin To 18 States

by IANS - May 12, 2021 10:47 AM +05:30 IST
Bharat Biotech Supplying Its Covid-19 Vaccine Covaxin To 18 StatesBharat Biotech’s COVAXIN, India’s first indigenous vaccine against coronavirus. (Swarajya Magazine)

Bharat Biotech has been directly supplying its Covid-19 vaccine Covaxin to 18 states since 1 May, the company said on Tuesday (11 May).

"Unflinching in our efforts, we will continue the steady supply of our vaccine," the Hyderabad-based vaccine maker tweeted.

The states are Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu & Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh and West Bengal.

The company, however, has not come out with details of the supplies like the number of doses supplied to the states.

The company earlier said it started the supplies based on the allocations received by the Government of India.

"Requests have been received from other states, & will be processed for distribution based on availability of stocks 24x7," Bharat Biotech co-founder and Joint Managing Director Suchitra Ella had tweeted earlier.

Bharat Biotech had on 24 April announced pricing for Covaxin. It fixed the price of Covaxin at Rs.600 per dose for state governments.

However, it later slashed the price to Rs 400. This came after Serum Institute of India (SII) cut the price of Covishield to Rs 300 from Rs 400 earlier.

The two vaccine makers slashed the prices after the central government reportedly made a request to them amid the row over different pricing for the central and state governments.

For private hospitals, Bharat Biotech fixed the price at Rs.1,200 per dose. This is twice the cost fixed for Covishield.

For exports, Bharat Biotech has priced India's first indigenous Covid vaccine at $15-$20 (Rs 1,125-1,500).

Ever since the launch of Covid vaccination programme in India, Bharat Biotech and SII have been supplying their vaccines to the Centre at Rs 150 per dose.

While Bharat Biotech is likely to continue the supplies to the Centre at the same price, SII is seeking to revise this to Rs 400.

Both Bharat Biotech and SII have announced that they are reserving 50 per cent of their production capacities for supplies to the central government.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)

Get Swarajya in your inbox everyday. Subscribe here.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber
Comments ↓
Get Swarajya in your inbox everyday. Subscribe here.

Latest Articles

    Artboard 4Created with Sketch.